Leukocytoclastic Vasculitis in Cutaneous Crohn Disease in the Setting of COVID-19

Nassani, Najib; Sweiss, Nadera J.; Berry, John Thomas; Calhoun, C.; Polick, Anne; Trivedi, Itishree

doi:10.1093/ibd/izab045

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rituximab has been used in cases associated with systemic vasculitides or malignancies, particularly hematologic [12]. In severe refractory cases of COVID-related vasculitis and cutaneous vasculitis, plasma exchange or intravenous immunoglobulin (IVIG) have also been beneficial [13,14]. For maintenance therapy, if an anti-TNF agent is considered the primary cause of the vasculitis, switching to a treatment not directed at TNF is typically recommended, although there have been reports of small subsets of patients experiencing resolution of their LCV even while continuing the same anti-TNF therapy [13].…”

Section: Discussionmentioning

confidence: 99%

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease

et al. 2023

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease

et al. 2023

View full text Add to dashboard Cite

“…Clinical appearance spans from classic, bilateral symmetric palpable purpura favoring dependent body sites ( Supplementary Figures 1a,b ) to vesicobullous, hemorrhagic or targetoid eruptions. Oral or intravenous CS, with or without topical CS, were the mainstay of treatment, whereas intravenous immunoglobulin (IVIg) was employed only in a minority of cases ( 19 , 20 , 23 ). As for the prognosis, most patients experienced complete recovery, except for a few who developed vasculitis-associated gangrene or died due to COVID-19-related complications ( 12 , 19 , 20 , 24 ).…”

Section: Covid-19-associated Cutaneous Vasculitis/vasculopathymentioning

confidence: 99%

Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic

et al. 2022

View full text Add to dashboard Cite

Cutaneous vasculitides encompass a heterogeneous group of clinicopathological entities, which may occur as single-organ vasculitis of the skin or present as skin-limited variant of systemic vasculitis (i.e., skin-limited ANCA-associated vasculitis), and are triggered by various factors, including infections, drugs and vaccines. The COVID-19 pandemic has challenged us with a variety of both disease- and vaccine-associated skin manifestations, including vasculitis. Among the latter, cutaneous small-vessel vasculitis, previously known as leukocytoclastic vasculitis, seems to be the most reported in either scenario, i.e., natural infection and vaccination. Vasculopathy without true vasculitic changes on histology develops in but a minority of cases, mostly severe/critical COVID-19 patients, and appears to be the result of endothelial injury due to pauci-immune thromboembolic mechanisms. Herein, we provide an overview of the available literature on COVID-19-associated and anti-SARS-CoV-2-vaccine-associated cutaneous vasculitis. Although evidence is mostly limited to isolated reports, with a proportion of cases lacking histopathological confirmation, ample overlap with pre-pandemic forms is shown.

show abstract

Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination

et al. 2022

View full text Add to dashboard Cite

Cutaneous vasculitis (CV) is an inflammatory skin-limited vascular disease affecting the dermal and/or hypodermal vessel wall. From the pathogenetic point of view, idiopathic forms are described as well as the induction from various triggers, such as drugs, infections, and vaccines. Following SARS-CoV-2 pandemic outbreak, cases of CV induced by both COVID-19 and COVID-19 vaccinations have been reported in literature. The aim of our work was to collect multiple cases available in the literature and analyze the frequency of the different forms of induced vasculitis, as well as their histological and immunopathological features. Although rare, CV induced by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and vaccines may provide interesting insights into the pathogenesis of these inflammatory processes that may in the future be useful to understand the mechanisms underlying cutaneous and systemic vasculitis.

show abstract

Leukocytoclastic Vasculitis in Cutaneous Crohn Disease in the Setting of COVID-19

Cited by 3 publications

References 4 publications

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease

Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic

Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination

Contact Info

Product

Resources

About